Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Client Work

Transition Therapeutics completes $25 million private placement

Fasken
Reading Time 1 minute read Subscribe
On November 8, 2006, Transition Therapeutics Inc., a biopharmaceutical company developing novel therapeutics for disease indications with large markets, announced the closing of its previously disclosed private placement financing. It issued 26,881,720 common shares at a price of $0.93 per common share, raising gross proceeds of $25 million from two funds managed by Great Point Partners, LLC. The proceeds from the offering will be used to fund Transition's clinical studies, research and product development, working capital and general corporate purposes. Stephen Erlichman and John Sabetti of Fasken Martineau acted as Canadian legal advisors to Great Point Partners in this transaction.

    Subscribe

    Receive email updates from our team

    Subscribe